Lexaria Capital Lease Obligations from 2010 to 2025
| LEXXW Stock | USD 0.40 0.07 21.21% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 158 K | Current Value 124.6 K | Quarterly Volatility 25.3 K |
Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 129 K, Interest Expense of 125.2 K or Other Operating Expenses of 7.5 M, as well as many indicators such as Price To Sales Ratio of 140, Dividend Yield of 0.0 or PTB Ratio of 57.61. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
Lexaria | Capital Lease Obligations |
Latest Lexaria Bioscience's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Lexaria Bioscience Corp over the last few years. Lexaria Bioscience Corp capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Lexaria Bioscience asset purchases. For example, Lexaria Bioscience can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Lexaria Bioscience control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Lexaria Bioscience's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexaria Bioscience's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Lexaria Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 123,597 | |
| Geometric Mean | 120,240 | |
| Coefficient Of Variation | 20.49 | |
| Mean Deviation | 13,477 | |
| Median | 125,431 | |
| Standard Deviation | 25,329 | |
| Sample Variance | 641.6M | |
| Range | 114K | |
| R-Value | 0.05 | |
| Mean Square Error | 685.7M | |
| R-Squared | 0 | |
| Significance | 0.86 | |
| Slope | 264.20 | |
| Total Sum of Squares | 9.6B |
Lexaria Capital Lease Obligations History
About Lexaria Bioscience Financial Statements
Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 158 K | 124.6 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.